Table 3 Adjunctive metformin for antipsychotic-induced dyslipidemia: secondary outcomes.
Variables | Active arms (subjects) | SMDs/RRs (95%CI) | I2 (%) | P |
|---|---|---|---|---|
Clinical features | ||||
Body weight (kg) | 11 (1004) | −0.35 (−0.59, −0.11) | 69 | 0.005 |
BMI (kg/m2) | 12 (1016) | −0.39 (−0.66, −0.12) | 76 | 0.005 |
Waist circumference (cm) | 9 (681) | −0.15 (−0.45, 0.15) | 71 | 0.33 |
WHR | 3 (346) | −0.46 (−1.19, 0.27) | 91 | 0.22 |
Leptin (ug/L) | 3 (238) | −1.09 (−2.26, 0.07) | 94 | 0.07 |
Fasting glucose (mmol/L) | 13 (1161) | −0.31 (−0.67, 0.04) | 88 | 0.09 |
HbA1c (%) | 4 (384) | −0.32 (−0.52, −0.12) | 0 | 0.002 |
Fast insulin (mIU/L) | 5 (615) | −0.73 (−1.22, −0.24) | 87 | 0.003 |
HOMA-IR | 6 (501) | −0.89 (−1.57, −0.21) | 92 | 0.01 |
Diastolic blood pressure (mmHg) | 5 (371) | −0.11 (−0.31, 0.10) | 0 | 0.30 |
Systolic blood pressure (mmHg) | 5 (371) | −0.15 (−0.35, 0.06) | 0 | 0.16 |
Discontinuation rate | ||||
Discontinuation due to any reason | 9 (806) | 0.97 (0.66, 1.43) | 0 | 0.89 |
ADRs | ||||
Nausea/vomiting | 7 (765) | 1.51 (1.05, 2.16) | 0 | 0.02 |
Dizziness | 2 (315) | 1.99 (0.56, 7.06) | 0 | 0.29 |
Dry mouth | 4 (596) | 1.76 (0.82, 3.76) | 0 | 0.14 |
Hypersomnia | 2 (371) | 0.45 (0.02, 11.25) | 77 | 0.63 |
Tachycardia | 2 (315) | 0.86 (0.26, 2.83) | 16 | 0.80 |
Headache | 2 (316) | 1.02 (0.17, 6.05) | 44 | 0.98 |
Constipation | 3 (395) | 1.23 (0.52, 2.88) | 10 | 0.64 |
Diarrhea | 5 (394) | 1.43 (0.86, 2.41) | 19 | 0.17 |
